Ohe Y - Search Results

1

The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor.

Tagami K, Kashiwase Y, Yokoyama A, Nishimura H, Miyano K, Suzuki M, Shiraishi S, Matoba M, Ohe Y, Uezono Y. Tagami K, et al. Among authors: ohe y. Neuropeptides. 2016 Aug;58:93-101. doi: 10.1016/j.npep.2015.12.010. Epub 2015 Dec 22. Neuropeptides. 2016. PMID: 26775231

2

Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.

Hashimoto H, Abe M, Yanai T, Yamaguchi T, Zenda S, Uchitomi Y, Fukuda H, Mori M, Iwasa S, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2018 Oct 1;48(10):950-952. doi: 10.1093/jjco/hyy114. Jpn J Clin Oncol. 2018. PMID: 30124989 Clinical Trial.

3

Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.

Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A. Yoshida T, et al. Among authors: ohe y. Clin Cancer Res. 2015 Feb 1;21(3):642-51. doi: 10.1158/1078-0432.CCR-14-0846. Epub 2014 Nov 11. Clin Cancer Res. 2015. PMID: 25388165

4

Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth.

Takahashi A, Ishii G, Neri S, Yoshida T, Hashimoto H, Suzuki S, Umemura S, Matsumoto S, Yoh K, Niho S, Goto K, Ohmatsu H, Nagai K, Gemma A, Ohe Y, Ochiai A. Takahashi A, et al. Among authors: ohe y. Oncotarget. 2015 Apr 20;6(11):9531-41. doi: 10.18632/oncotarget.3371. Oncotarget. 2015. PMID: 25909164 Free PMC article.

5

Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

Zenke Y, Yoh K, Matsumoto S, Umemura S, Niho S, Ohmatsu H, Goto K, Ohe Y. Zenke Y, et al. Among authors: ohe y. Clin Lung Cancer. 2016 Sep;17(5):412-418. doi: 10.1016/j.cllc.2016.01.006. Epub 2016 Feb 5. Clin Lung Cancer. 2016. PMID: 26944770

6

Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M. Goto K, et al. Among authors: ohe y. J Thorac Oncol. 2012 Jan;7(1):115-21. doi: 10.1097/JTO.0b013e3182307f98. J Thorac Oncol. 2012. PMID: 21900837 Free article. Clinical Trial.

7

Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.

Sugiyama E, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Ohe Y, Goto K. Sugiyama E, et al. Among authors: ohe y. Lung Cancer. 2015 Nov;90(2):307-13. doi: 10.1016/j.lungcan.2015.08.004. Epub 2015 Aug 12. Lung Cancer. 2015. PMID: 26323212

8

Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.

Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Sci Rep. 2024 May 3;14(1):10162. doi: 10.1038/s41598-024-60833-w. Sci Rep. 2024. PMID: 38702426 Free PMC article.

9

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.

Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K, Takahashi K. Ando K, et al. Among authors: ohe y. PLoS One. 2014 Jul 10;9(7):e102436. doi: 10.1371/journal.pone.0102436. eCollection 2014. PLoS One. 2014. PMID: 25010770 Free PMC article.

10

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.

Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y. Kanda S, et al. Among authors: ohe y. Lung Cancer. 2015 Sep;89(3):287-93. doi: 10.1016/j.lungcan.2015.06.016. Epub 2015 Jul 2. Lung Cancer. 2015. PMID: 26169499

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

701 results

Search Page